MedTrace Logo

Intravenous Stem Cells After Ischemic Stroke

NCT00875654 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-11-01

No results posted yet for this study

Summary

The main objective of the study is to evaluate feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells for patients presenting an ischemic stroke (less than 6 weeks).

Conditions

Interventions

GENETIC

Autologous mesenchymal stem cells

Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume\<100ml) less than 6 weeks after stroke

Sponsors & Collaborators

  • Commissariat A L'energie Atomique

    collaborator OTHER_GOV

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Olivier Detante, MD · University Hospital, Grenoble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2017-10-20
Completion
2017-10-20

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875654 on ClinicalTrials.gov